Diamyd Medical
Manufacturing · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Kungsgatan 29, Stockholm, Stockholm, 111...Phone Number
+46 86610026Website
www.diamyd.comRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Diamyd Medical
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.Explore more
Diamyd Medical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Diamyd Medical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Diamyd Medical had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Diamyd Medical recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Diamyd Medical launches new products
Check if Diamyd Medical has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Diamyd Medical
Funding: Get notified immidiatlly once Diamyd Medical has new funding data
Diamyd Medical, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Diamyd Medical is spiking on competitors!
Recommended Actions
Find VP level buyers at Diamyd Medical
Find 3 more new buyers
Company Profile Activity
Activity Insights
Diamyd Medical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Diamyd Medical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Diamyd Medical.
Diamyd Medical Tech Stack
A closer look at the technologies used by Diamyd Medical
Most Recent Scoops
Open Position
Seeking Replacement
Executive Move
Executive Moves, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Diamyd Medical News & Media
Diamyd Medical AB (publ) (DYMDF) Discusses Surprising Futility Results in Phase III Trial of Retogatein for Type 1 Diabetes Transcript
Diamyd Medical AB (publ) (DYMDF) Discusses Surprising Futility Results in Phase III Trial of Retogatein for Type 1 Diabetes March 30, 2026 9:00 AM...Diamyd Medical enters into equity financing agreements with new U.S. sector specialist investors for up to USD 125 million and announces full enrollment in Phase 3 trial
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE...Diamyd Medical enters into equity financing agreements with new U.S. sector specialist investors for up to USD 125 million and announces full enrollment in Phase 3 trial
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE...Diamyd Medical Secures Up to $125 Million Financing Agreement and Completes Phase 3 ...
Diabetes research firm Diamyd Medical has completed a directed share issue of approximately 17.2 million B-shares at a price of SEK 13.54, raising roughly SEK 233 million before transaction costs....
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Diamyd Medical
Sign Up For FreeTo access detailed company insights
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which... Read More
